Prognostic factors in patients with cerebral sinus venous thrombosis presenting with hemorrhage and papilledema.


Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
11 2023
Historique:
received: 10 09 2023
revised: 03 10 2023
accepted: 08 10 2023
medline: 6 11 2023
pubmed: 17 10 2023
entrez: 16 10 2023
Statut: ppublish

Résumé

The thromboinflammatory process is considered to play a role in the pathogenesis and prognosis of cerebral sinus vein thrombosis (CSVT). The purpose of the study was to compare the thromboinflammatory parameters between individuals with CSVT and healty controls. Additionally, the study sought to compare these parameters among CSVT subgroups with and without haemorrhage, as well as with and without papilledema. Furthermore, the investigation also aimed to identify which parameters had a more significant impact on the risk of hemorrhage and the development of papilledema in CSVT. Thromboinflammatory parameters were compared retrospectively between the CSVT group of 88 patients and 80 age- and sex-matched healthy controls, and in the CSVT subgroups with (n = 35) /without hemorrhage (n = 53) and with (n = 52) /without papilledema (n = 36) after ethics committee approval. In both groups, parameters contributing to the risk of hemorrhage and papilledema development were determined by univariate and multivariate analyses. Regarding the risk of hemorrhage in CSVT patients, the most significant factors included hematocrit of <30.2 (%), mean platelet volume of ≤8.9 fL, neutrophil count of >5600, and hsCRP of >9 mg/L. Regarding the risk of papilledema development, the most important risk factors were age of ≤49, presence of vomiting, presence of blurred vision, HDL of >47 mg/dL, and D-dimer of >178 ng/mL. It was suggested that evaluating serum thromboinflammatory parameters, as well as demographic characteristics and neurological examination findings, had a critical role regarding prognosis and predictive factors in CSVT.

Identifiants

pubmed: 37844432
pii: S0303-8467(23)00429-8
doi: 10.1016/j.clineuro.2023.108013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108013

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

Ayşegül Şeyma Sarıtaş (AŞ)

Celal Bayar University Neurology Department Manisa, Turkey.

Melike Batum (M)

Celal Bayar University Neurology Department Manisa, Turkey.

Ceyla Ataç (C)

Izmir Bozyaka Training and Research Hospital Neurology Department, Turkey.

Üzeyir Öztürk (Ü)

Celal Bayar University Neurology Department Manisa, Turkey.

Hikmet Yılmaz (H)

Celal Bayar University Neurology Department Manisa, Turkey.

Hatice Mavioğlu (H)

Izmir Tinaztepe University Galen Hospital, Turkey.

Deniz Selçuki (D)

Izmir Tinaztepe University Galen Hospital, Turkey.

Ayşın Kısabay Ak (AK)

Celal Bayar University Neurology Department Manisa, Turkey. Electronic address: aysinkisabay@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH